Immune modulation following α and β− radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model

α- and β−-emitting radionuclides targeting human fibroblast activation protein-α (hFAP) are under investigation for cancer therapy. In prior work, analysis of the tumor microenvironment 24 h after therapy completion indicated therapy-induced immune activation. Here, we analyzed systemic immune respo...

Descripció completa

Dades bibliogràfiques

Autors principals:	Hannelore Ceuppens, Kirsten De Ridder, Thomas Ertveldt, Katty Zeven, Wout De Mey, Ana Rita Pombo Antunes, Laurent Navarro, Nina Dumauthioz, Tony Lahoutte, Jens M. Debacker, Nick Devoogdt, Marleen Keyaerts, Matthias D’Huyvetter, Cleo Goyvaerts, Karine Breckpot
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2025-12-01
Col·lecció:	OncoImmunology
Matèries:	fibroblast activation protein-α single domain antibody targeted radionuclide therapy immunostimulation immunotherapy cGAS-STING
Accés en línia:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2540054
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!